- An Extension Study to Evaluate the Long-Term Safety of FCFD4514S in Patients With Geographic AtrophyCondition: Geographic Atrophy
Intervention: Drug: FCFD4514S
Sponsors: Genentech; Genentech
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012 - Condition: Stroke
Intervention: Drug: Tissue plasminogen activator (Activase®)
Sponsors: Seattle Children's Hospital; Seattle Children's Hospital; The Hospital for Sick Children; Medical College of Wisconsin; University of Texas at Austin; Alberta Children's Hospital; McMaster University
Not yet recruiting - verified May 2012 - Condition: Neoplasms
Intervention: Drug: bevacizumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Malignant Melanoma
Intervention: Drug: Zelboraf (vemurafenib)
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012 - Condition: Retinal Vein Occlusion
Intervention: Drug: Dexamethasone with rescue ranibizumab
Sponsors: Wills Eye; Wills Eye
Not yet recruiting - verified April 2012 - Conditions: Retroperitoneal Fibrosis; Autoimmune Pancreatitis; Sialadenitis; Pseudotumor
Intervention: Drug: Rituximab
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Genentech
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199; Drug: Bendamustine; Drug: Rituximab
Sponsors: Abbott; Abbott; Genentech
Not yet recruiting - verified May 2012 - Condition: Head and Neck Cancer
Interventions: Drug: MEHD7945A; Drug: cetuximab
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012 - Condition: Lymphoma, Solid Tumour
Interventions: Drug: GDC-0575; Drug: gemcitabine
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Neoplasms
Interventions: Drug: GDC-0973; Drug: GDC-0068
Sponsors: Genentech; Genentech
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Herceptin; Drug: NeuVax vaccine; Drug: GM-CSF
Sponsors: San Antonio Military Medical Center; COL George Peoples, MD, FACS; Genentech; Galena Biopharma, Inc.
Not yet recruiting - verified April 2012 - Conditions: Basal Cell Nevus Syndrome; Gorlin's Syndrome
Interventions: Drug: GDC-0449; Procedure: Aminolevulinic acid %20 topical solution + blue light
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland; Genentech
Not yet recruiting - verified March 2012 - Condition: Glioblastoma, Glioma
Intervention: Drug: GDC-0084
Sponsors: Genentech; Genentech
Recruiting - verified May 2012 - Condition: Solid Cancers
Intervention: Drug: Vismodegib
Sponsors: Genentech; Genentech
Not yet recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: MCAF5352A; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Diabetic Macular Edema
Interventions: Drug: 0.50mg ranibizumab; Procedure: Targeted Pan Retinal Photocoagulation
Sponsors: Greater Houston Retina Research; David M. Brown, M.D.; Genentech
Recruiting - verified March 2012 - Conditions: Recurrent/Refractory CNS; Intraocular Lymphoma
Interventions: Drug: Lenalidomide; Drug: Rituximab
Sponsors: University of California, San Francisco; James Rubenstein; University of California, San Francisco; Celgene Corporation; Genentech
Not yet recruiting - verified March 2012 - Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Cu-64 Rituximab
Sponsors: Stanford University; Sanjiv Sam Gambhir
Recruiting - verified May 2012 - Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; Genentech
Not yet recruiting - verified March 2012 - Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: Intravitreal injection of Aflibercept
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012 - Condition: Malignant Melanoma
Intervention: Drug: DEDN6526A
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Non Small Cell Lung Cancer
Intervention:
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Genentech
Not yet recruiting - verified March 2012 - Condition: Diabetic Retinopathy
Intervention: Drug: bevacizumab
Sponsors: Kyungpook National University; Kyungpook National University
Recruiting - verified January 2012 - Condition: Healthy Volunteer
Interventions: Drug: RG7667; Drug: Placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified December 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Condition: Healthy Volunteer
Intervention: Drug: [14C]-GDC-0980
Sponsors: Genentech; Genentech
Not yet recruiting - verified December 2011 - Conditions: Neuroblastoma; Sarcoma
Intervention: Drug: Cyclophosphamide, Topotecan, and Bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Children's Mercy Hospital Kansas City; Penn State University; University of Colorado Health Sciences Center and The Children's Hospital; Johns Hopkins Medical Center Sidney Kimmel Comprehensive Cancer Center; Phoenix Children's Hospital Center for Cancer & Blood Disorders; Alberta Children's Hospital; MD Anderson Cancer Center Orlando; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Prostate Cancer
Interventions: Drug: GDC-0068; Drug: GDC-0980; Drug: placebo; Drug: abiraterone; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Conditions: Melanoma; Metastatic Melanoma
Interventions: Drug: Vemurafenib; Drug: Bevacizumab
Sponsors: Melanoma Research Foundation Breakthrough Consortium; Melanoma Research Foundation Breakthrough Consortium; Genentech
Not yet recruiting - verified April 2012 - Condition: Proliferative Diabetic Retinopathy
Interventions: Other: Prompt Panretinal Photocoagulation; Drug: 0.5-mg Ranibizumab; Other: Deferred panretinal photocoagulation
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); Genentech
Recruiting - verified March 2012 - Condition: Healthy Volunteer
Interventions: Drug: MCAF5352A; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified December 2011 - Condition: Healthy Volunteer
Intervention: Drug: GDC-0941
Sponsors: Genentech; Genentech
Completed - verified December 2011 - Condition: Healthy
Interventions: Drug: MLDL1278A; Drug: MLDL1278A
Sponsors: BioInvent International AB; BioInvent International AB; Genentech
Active, not recruiting - verified March 2012 - Condition: Healthy Volunteer
Interventions: Drug: GDC-0980; Drug: Ketoconazole
Sponsors: Genentech; Genentech
Not yet recruiting - verified November 2011 - Conditions: Ovarian Cancer; Pancreatic Cancer
Intervention: Drug: DMOT4039A
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Melanoma
Intervention: Drug: vemurafenib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified November 2011 - Conditions: Diabetic Retinopathy; Macular Edema
Interventions: Drug: Ranibizumab; Drug: Ranibizumab
Sponsors: Retina Vitreous Associates of Florida; Retina Vitreous Associates of Florida; Genentech
Recruiting - verified November 2011 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving BevacizumabConditions: Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion; Macular Edema
Interventions: Drug: ranibizumab 0.5mg; Drug: ranibizumab 1.0mg
Sponsors: Hanscom, Thomas, M.D.; Hanscom, Thomas, M.D.; Genentech
Recruiting - verified November 2011 - Condition: Diabetic Macular Edema
Interventions: Drug: Ranibizumab; Drug: Ranibizumab
Sponsors: Vitreo-Retinal Associates, PC; Vitreo-Retinal Associates, PC; Genentech
Recruiting - verified January 2012 - Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc
Sponsors: Southeast Retina Center, Georgia; Southeast Retina Center, Georgia; Genentech
Recruiting - verified November 2011 - Condition: Age-Related Macular Degeneration
Intervention: Drug: ranibizumab
Sponsors: University of California, San Diego; University of California, San Diego; Genentech
Active, not recruiting - verified November 2011 - Condition: Age-related Macular Degeneration
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; Genentech
Enrolling by invitation - verified November 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012 - Condition: Endometrial Carcinoma
Intervention: Drug: GDC-0980
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Ulcerative Colitis
Intervention: Drug: rhuMAb Beta7
Sponsors: Genentech; Genentech
Not yet recruiting - verified October 2011 - Conditions: Macular Edema; Retinal Vein Occlusion
Intervention: Drug: Ranibizumab 0.5 mg
Sponsors: Genentech; Genentech
Completed - verified December 2011 - Condition: Stroke
Interventions: Drug: Anti-platelets and statin; Drug: alteplase; Procedure: intra arterial intervention
Sponsors: Jacobs Neurological Institute; Jacobs Neurological Institute; University at Buffalo Neurosurgery; Genentech
Recruiting - verified March 2012 - Condition: Renal Cell Carcinoma
Interventions: Drug: everolimus; Drug: GDC-0980
Sponsors: Genentech; Genentech
Not yet recruiting - verified September 2011 - Condition: Asthma
Intervention: Other: Real-time asthma care outreach
Sponsors: Kaiser Permanente; Kaiser Permanente; Genentech
Enrolling by invitation - verified October 2011 - Condition: Primary Open Angle Glaucoma
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; Genentech
Recruiting - verified September 2011 - Conditions: Sepsis; Acute Lung Injury; Acute Respiratory Distress Syndrome
Interventions: Biological: TNX-832; Drug: Placebo
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; Genentech; Tanox
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention: Drug: DFRF4539A
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: navitoclax; Drug: bendamustine; Drug: rituximab
Sponsors: Genentech; Genentech; Abbott
Withdrawn - verified April 2012 - Condition: Complications of Diabetes Mellitus
Intervention: Drug: Intravitreal Avastin injection
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital
Recruiting - verified September 2011 - Condition: Paget's Disease of the Vulva
Intervention: Drug: trastuzumab
Sponsors: Yale University; Yale University; Genentech
Recruiting - verified August 2011 - Condition: Ovarian Cancer
Intervention:
Sponsors: Genentech; Genentech
Not yet recruiting - verified August 2011 - Condition: Healthy Volunteer
Interventions: Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Active, not recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: Placebo; Drug: bevacizumab [Avastin]; Drug: FOLFOX regimen; Drug: leucovorin; Drug: 5-FU
Sponsors: Genentech; Genentech; Sarah Cannon Research Institute
Recruiting - verified January 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: RO50722759; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: RO5072759
Sponsors: Genentech; Genentech
Recruiting - verified November 2011 - Condition: Atopic Asthma
Interventions: Procedure: Bone Marrow Aspiration; Procedure: Tonsil Biopsy
Sponsors: Hamilton Health Sciences Corporation; Hamilton Health Sciences Corporation; Genentech
Recruiting - verified April 2012 - Condition: Diabetes Complications
Intervention: Drug: Avastin (bevacizumab)
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital
Recruiting - verified September 2011 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Conditions: Hereditary Hemorrhagic Telangiectasia (HHT); Nosebleeds
Intervention: Drug: Ranibizumab
Sponsors: University of California, San Diego; University of California, San Diego; Genentech
Withdrawn - verified May 2012 - Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A; Drug: MABT5102A; Drug: placebo; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified August 2011 - Condition: Age-Related Macular Degeneration
Intervention: Drug: ranibizumab
Sponsors: University of California, San Diego; University of California, San Diego; Genentech
Recruiting - verified July 2011 - Condition: Melanoma
Interventions: Drug: Ipilimumab (BMS-734016); Biological: Vemurafenib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Roche-Genentech
Recruiting - verified November 2011 - Condition: Polymyalgia Rheumatica (PMR)
Intervention: Drug: Tocilizumab
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; Genentech
Recruiting - verified January 2012 - Conditions: Brain Cancer; MALIGNANT GLIOMA; Glioblastoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Anaplastic Oligo-astrocytoma (AOA); Anaplastic Mixed Gliomas; Malignant Glioma NOS
Intervention: Other: Bevacizumab & stereotactic radiotherapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Columbia University; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: Dasatinib; Drug: Dasatinib plus Rabeprazole; Drug: Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Sponsors: University of California, San Francisco; University of California, San Francisco; Genentech
Recruiting - verified November 2011 - Condition: Solid Cancers
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011 - Condition: Prematurity of Fetus
Intervention: Drug: Oseltamivir
Sponsors: St. Louis Children's Hospital; St. Louis Children's Hospital; Genentech; Washington University School of Medicine
Completed - verified June 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: MEGF0444A; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid TumorsCondition: Solid Tumour
Intervention: Drug: MFGR1877S
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Solid Cancers
Interventions: Drug: docetaxel; Drug: GDC-0068; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer, Ovarian Cancer
Intervention: Drug: DNIB0600A
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Moderate to Severe Allergic Asthma
Intervention:
Sponsors: Novartis; Novartis Pharmaceuticals; Genentech
Completed - verified June 2011 - Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel; Drug: Trastuzumab
Sponsors: Yale University; Yale University; Genentech
Recruiting - verified January 2012
 |
Genentech - Database of Clinical Trials by Pharmaceutical Companies |
